![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » FDA Pushes Back Comment Period for Biosimilar Labeling
FDA Pushes Back Comment Period for Biosimilar Labeling
June 9, 2016
The FDA is extending the comment period for its draft guidance on labeling for biosimilars by 60 days to Aug. 2.
The agency had asked for feedback from industry in April on the guidance, which recommends that biosimilars sponsors put information from the reference product labeling on the labeling for the biosimilar product.
Interested parties can submit comments here: https://www.regulations.gov/#!documentDetail;D=FDA-2016-D-0643-0001.
Upcoming Events
-
21Oct